The bill amends sections 3902.50 and 3902.70 of the Revised Code and enacts a new section 3902.72, which prohibits drug manufacturers from engaging in certain actions regarding the acquisition and delivery of drugs to 340B covered entities. Specifically, it prevents manufacturers, repackagers, and third-party logistics providers from denying or limiting the acquisition of 340B drugs by these entities, as well as from requiring them to submit claims or utilization data as a condition for drug acquisition. The bill also establishes definitions for terms related to the 340B drug pricing program and outlines penalties for violations, including civil penalties and potential referral to the state board of pharmacy.

Additionally, the bill updates the numbering of sections, replacing the previous section 3902.72 with 3902.75, and introduces new requirements for health plan issuers and pharmacy benefit managers regarding the provision of data related to covered drugs. This includes obligations to furnish eligibility and cost-sharing information, ensure data is current and provided in real-time, and not to hinder communication between healthcare providers and covered persons. The provisions of the new section are set to take effect on January 1, 2022, while existing sections 3902.50, 3902.70, and 3902.72 are repealed.

Statutes affected:
As Introduced: 3902.50, 3902.70, 3902.72, 3902.75